Insights Into GLP-1 and GIP Actions Emerging From Vildagliptin Mechanism Studies in Man

por Foley, James E.
Publicado 2019

Weight neutrality with the DPP-4 inhibitor, vildagliptin: Mechanistic basis and clinical experience

por Foley, James E, Jordan, Jens
Publicado 2010

Estimation of the Relative Contribution of Postprandial Glucose Exposure to Average Total Glucose Exposure in Subjects with Type 2 Diabetes

por Ahrén, Bo, Foley, James E.
Publicado 2016

The Vildagliptin Experience — 25 Years Since the Initiation of the Novartis Glucagon-like Peptide-1 Based Therapy Programme and 10 Years Since the First Vildagliptin Registration

por Foley, James E, Ahrén, Bo
Publicado 2017

Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus

por Dejager, Sylvie, Schweizer, Anja, Foley, James E
Publicado 2012

Impact of Insulin Resistance, Body Mass Index, Disease Duration, and Duration of Metformin Use on the Efficacy of Vildagliptin

por Schweizer, Anja, Dejager, Sylvie, Foley, James E.
Publicado 2012

Does the treatment of type 2 diabetes mellitus with the DPP-4 inhibitor vildagliptin reduce HbA1c to a greater extent in Japanese patients than in Caucasian patients?

por Foley, James E, Bhosekar, Vaishali, Kawamori, Ryuzo
Publicado 2016

Blood pressure and fasting lipid changes after 24 weeks’ treatment with vildagliptin: a pooled analysis in >2,000 previously drug-naïve patients with type 2 diabetes mellitus

por Evans, Marc, Schweizer, Anja, Foley, James E
Publicado 2016

DPP-4 inhibitor treatment: β-cell response but not HbA(1c) reduction is dependent on the duration of diabetes

por Kozlovski, Plamen, Bhosekar, Vaishali, Foley, James E
Publicado 2017

Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies

por Schweizer, Anja, Dejager, Sylvie, Foley, James E, Kothny, Wolfgang
Publicado 2011

Clinical evidence and mechanistic basis for vildagliptin’s effect in combination with insulin

por Schweizer, Anja, Foley, James E, Kothny, Wolfgang, Ahrén, Bo
Publicado 2013

Changes in body weight after 24 weeks of vildagliptin therapy as a function of fasting glucose levels in patients with type 2 diabetes

por Blüher, Matthias, Schweizer, Anja, Bader, Giovanni, Foley, James E
Publicado 2014

Is There Evidence of Any Safety Differences Among DPP-4 Inhibitors in the Treatment of People with Type 2 Diabetes Mellitus and Reduced GFR Due to Chronic Kidney Disease?

por Evans, Marc, Dejager, Sylvie, Schweizer, Anja, Foley, James E.
Publicado 2015

Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial

por Kothny, Wolfgang, Lukashevich, Valentina, Foley, James E., Rendell, Marc S., Schweizer, Anja
Publicado 2015

Four-Point Preprandial Self-Monitoring of Blood Glucose for the Assessment of Glycemic Control and Variability in Patients with Type 2 Diabetes Treated with Insulin and Vildaglipti...

por Tura, Andrea, Farngren, Johan, Schweizer, Anja, Foley, James E., Pacini, Giovanni, Ahrén, Bo
Publicado 2015

Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment

por Lukashevich, Valentina, Schweizer, Anja, Foley, James E, Dickinson, Sheila, Groop, Per-Henrik, Kothny, Wolfgang
Publicado 2013

Factors that may Account for Cardiovascular Risk Reduction with a Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin, in Young Patients with Type 2 Diabetes Mellitus

por Evans, Marc, Kozlovski, Plamen, Paldánius, Päivi M., Foley, James E., Bhosekar, Vaishali, Serban, Carmen, Avogaro, Angelo
Publicado 2017

Clinical Safety and Tolerability of Vildagliptin — Insights from Randomised Trials, Observational Studies and Post-marketing Surveillance

por Mathieu, Chantal, Kozlovski, Plamen, Paldánius, Päivi M, Foley, James E, Modgill, Vikas, Evans, Marc, Serban, Carmen
Publicado 2017

Changes in Prandial Glucagon Levels After a 2-Year Treatment With Vildagliptin or Glimepiride in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy

por Ahrén, Bo, Foley, James E., Ferrannini, Ele, Matthews, David R., Zinman, Bernard, Dejager, Sylvie, Fonseca, Vivian A.
Publicado 2010

Effect of Vildagliptin on Hepatic Steatosis

por Macauley, Mavin, Hollingsworth, Kieren G., Smith, Fiona E., Thelwall, Peter E., Al-Mrabeh, Ahmad, Schweizer, Anja, Foley, James E., Taylor, Roy
Publicado 2015